Skip to main navigation
Skip to search
Skip to main content
Universitat Autònoma de Barcelona Research Portal Home
Help & FAQ
Català
Español
English
Home
Profiles
Research units
Projects
Research output
Datasets
Student theses
Search by expertise, name or affiliation
Innovative methodologies and therapeutic agents for neurological disorders
Alibes Arques, Ramon
(Principal Investigator)
Busque Sanchez, Felix
(Principal Investigator 2)
Figueredo Galimany, Marta
(Investigator)
Casagualda Clapes, Carolina
(Collaborator)
Gomez Ventura, Marc
(Collaborator)
Novio Vazquez, Fernando
(Collaborator)
SERRANO GARCIA, ARNAU
(Collaborator)
Sanchez Morales, Adria
(Collaborator)
Illa Soler, Ona
(Investigator)
Department of Chemistry
Catalan Institute of Nanoscience and Nanotechnology (ICN2)
Overview
Fingerprint
Research output
(1)
Project Details
Status
Finished
Effective start/end date
1/06/20
→
31/12/23
View all
View less
Fingerprint
Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.
Pharmacokinetic Properties
Keyphrases
100%
Aggregation Inhibitor
Keyphrases
100%
Transthyretin
Keyphrases
100%
High Affinity
Keyphrases
100%
Clinical Trials
Keyphrases
28%
Clinical Trial
Biochemistry, Genetics and Molecular Biology
22%
Wild Type
Biochemistry, Genetics and Molecular Biology
22%
Rational Design
Keyphrases
14%
Research output
Research output per year
2023
2023
2023
1
Article
Research output per year
Research output per year
PITB : A high affinity transthyretin aggregation inhibitor with optimal pharmacokinetic properties
Pinheiro, F., Varejão, N., Sánchez-Morales, A., Bezerra, F., Navarro, S., Velázquez-Campoy, A.,
Busqué Sánchez, F.
, Almeida, M. R.,
Alibes, R.
,
Reverter, D.
,
Pallarès i Goitiz, I.
&
Ventura, S.
,
5 Dec 2023
,
In:
CHIM.THER..
261
,
10 p.
, 115837.
Research output
:
Contribution to journal
›
Article
›
Research
›
peer-review
Open Access
Pharmacokinetic Properties
100%
High Affinity
100%
Transthyretin
100%
Aggregation Inhibitor
100%
Clinical Trials
28%
1
Citation (Scopus)